Trial Profile
CONKO-005:Adjuvant Therapy in R0-resected Pancreatic Cancer Patients with Gemcitabine plus Erlotinib vs. Gemcitabine over 24 Weeks - a Prospective, Randomized Phase III Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CONKO-005
- 29 Apr 2021 Results of pooled analysis from three clinical studies: CONKO-001, CONKO-005, and CONKO-006 published in the European Journal of Cancer
- 17 Aug 2017 Results published in the Journal of Clinical Oncology
- 30 Jun 2015 Status changed from recruiting to completed, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.